Diabetes Mellitus at an Elderly Age

Due to the good medical care in Germany, many people with diabetes mellitus now reach old age: Of the 340,000 adults with type 1 diabetes, more than 100,000 are over 70 years of age. Approximately 8 million people have type 2 diabetes and one-fourth of this group is over 75 years of age, and approximately 1 million over the age of 80 [1].

Nationwide, there are a total of about 630,000 people with diabetes mellitus in need of care. The statements in the practice recommendations are mainly directed at the majority of elderly people with type 2 diabetes and can only reflect some of the special characteristics of elderly people with diabetes. Topics such as type 1 diabetes at an elderly age, end of life, interface management or ethics are covered in the complete S2k guideline.

The geriatric patient is defined by multimorbidity and a higher age. Age-typical functional limitations and high vulnerability create a special need for action that goes beyond blood glucose control and the management of cardiovascular risk factors or diabetes-typical complications. For differentiated therapy planning, elderly patients should be divided into functional groups ([Tab. 1]).

Tab. 1 Classification into functional groups.

Patient group	Patient description
Functionally independent	Elderly people with diabetes mellitus and good functional status. Patients with low comorbidity, at best low cognitive impairment and good compensation possibilities
Functionally slightly dependent	Elderly people with diabetes mellitus and limited functional status. Patients with multimorbidity, functional and cognitive limitations and geriatric syndromes
Functionally highly dependent	Elderly people with diabetes mellitus and extremely limited functional status or terminally ill people. Patients with multimorbidity, geriatric symptoms, pronounced functional and cognitive limitations and the presence of diseases with limited life prognosis, e. g. terminal heart, kidney or malignant diseases
End of life	People who are on their deathbed

A geriatric assessment should be conducted to determine resources and deficits (division into functional groups) (Practice Tool 1, see Appendix).

Treatment objectives

Goals are to be agreed individually from the point of view of participatory decision-making and on the basis of the personal risk profile between doctor and patient. Resources and deficits as well as geriatric syndromes play a role. Maintaining quality of life and avoiding hypoglycemia are the primary therapeutic goals. Individual aspects of quality of life should therefore be actively investigated. The HbA1c value is less important in advanced age for therapy decisions [2]. The HbA_1c value also has a limited informative value in renal insufficiency in old age.

The National Disease Management Guideline (Nationale Versorgungsleitlinien, NVL) recommends an HbA1c corridor between 6.5–8.5% depending on quality of life, comorbidity, polymedication, risk of hypoglycemia and drug side effects, burden of therapy, resources and possibilities of support, functional and cognitive abilities, duration of diabetes and patient desire (Practice Tool Fig. 3). This means lower functional and cognitive abilities do not automatically lead to choosing a higher therapeutic goal if resources of support are given.

The focus is on preventing hypoglycemia ([Fig. 1]). Lower HbA1c or pre- and postprandial values should only be targeted in therapies without a risk of hypoglycemia. The corresponding target corridors are shown in [Tab. 2].

Fig. 1 HbA_1c corridors by functionality with strict avoidance of hypoglycemia.

Tab. 2 Target corridors for elderly people with diabetes. ESC=European Society of Cardiology; ESH=European Society of Hypertension; HYVET=Hypertension in the Very Elderly Trial.

Patient group	Reasoning	HbA1c	Blood glucose before meals	Blood pressure (HYVET target values apply for 80+year olds)
Few concomitant diseases Cognitively not restricted (functionally independent patients)	Life expectancy>15 years Advantages of an intensive therapy can be experienced	6.5–7.5% (47.5–58.5 mmol/mol)	100–125 * mg/dl 5.6–6.9 mmol/l	Over 80 years old:<150 mmHg 60–80 years old:<140* mmHg (ESC/ESH)
Very old, or multimorbid or slightly cognitively-impaired patients (functionally slightly dependent patients)	Life expectancy<15 years Patient cannot live long enough to benefit from an intensive therapy. Increased risk of hypoglycemia and falls	≤8.0% (63.9 mmol/mol)	100* -150 mg/dl 5.6–8.3 mmol/l	<150 mmHg
Patients who are dependent on nursing care or cognitively severely restricted (functionally highly-dependent patients)	Limited life expectancy	<8.5% (69.4 mmol/mol)	110–180 mg/dl 6.1–10 mmol/l	Individual therapy decision that takes into account the overall context of the patient (as there is no target value evidence)
End of Life	Individually with the goal of freedom of symptoms

* Lower blood glucose limits apply only during hypoglycemic therapy.

General therapeutic goals regarding the improvement of quality of life are contained in Practice Tool 2 (see Attachment).

Individualized therapy goals should be agreed for the following parameters in elderly people with type 2 diabetes:

• Glucose metabolism

• Blood pressure

• Lipid profile

Hypoglycemia

The risk of hypoglycemia increases with diabetes duration and is higher in elderly people with diabetes [3]. The threshold for the perception of low blood glucose levels decreases with age; however, brain dysfunction already occurs at higher levels. In addition, the symptoms of hypoglycemia can take on a different form.

Hypoglycemia is the second most common cause of drug-related emergency admissions of elderly people [4]. The incidence of severe hypoglycemia is very high, at 7.8% per patient per year in nursing homes. Severe hypoglycemia is much more common in depression, kidney and heart failure and treatment with a beta-blocker. They are most common in treatments with prandial insulin, a basal insulin or insulin secretion; other antidiabetic treatments are associated with only a very low risk of hypoglycemia. Elderly people with concomitant diseases, multimorbidity or impaired cognitive performance are particularly at risk.

Hypoglycemia is much more common in everyday life than previously thought, especially at night. Risk factors are long duration of illness, cognitive impairment and multimorbidity, especially renal failure. There is increasing evidence that hypoglycemia promotes the development of cardiovascular events and dementia in advanced age [6]. The prevention of hypoglycemia is a primary therapeutic goal, especially for elderly people with diabetes. Therefore, the metabolic therapy goals and the implementation of therapy should be based on the functional resources and deficits of the patient. Therapy forms with the lowest possible risk of hypoglycemia should be chosen.

Hypertension

• Elderly patients benefit from effective blood pressure reduction. This also applies to patients over 80 years of age in good physical and mental condition [7].

• There is only insufficient evidence for antihypertensive treatment in frail patients over 80 years of age, so that this therapy should be individualized (see [Tab. 1]).

• There is no evidence for the different efficacy of antihypertensive drugs in younger or elderly patients. All major antihypertensive classes can be recommended.

Due to frequent comorbidities and polypharmacy, special attention should be paid to known adverse drug reactions in elderly patients.

Dyslipidemia

• In elderly patients with diabetes as well as very high risk (e. g. coronary heart disease (CHD), severe kidney damage or one or more cardiovascular (CV) risk factors and/or organ damage) a target low-density lipoprotein (LDL) cholesterol of<1.8 mmol/L (<70 mg/dL) or a LDL cholesterol reduction≥50% should be aimed for.

• In elderly patients with diabetes without functional limitations (without other CV risk factors and without organ damage) a target LDL cholesterol of<2.5 mmol/L (<100 mg/dL) should be aimed for.

• For elderly patients with functional limitations, the use of statins should be evaluated on an individual basis.

• Statins should be used as first-line therapy to lower LDL cholesterol.

Multi-medication

Prescription of more than five drugs increases the probability of occurrence of undesirable, clinically-relevant side effects/interactions (e. g. severe hypoglycemia, comorbidity) and reduces patient adherence. However, not only multi-medication should be considered. Due to incorrect medications such as. e. g. overdose of psychiatric drugs or sleeping pills, there is often a lack of indicated cardioprotective drugs in old age if cardiovascular concomitant diseases are present.

• The treatment regimen should be based on the patient’s wishes, current quality of life and self-care abilities, as well as the individual risk and resource profile of the patient.

• The drug therapy should be reviewed critically on a regular basis.

• Drug dosages must be adjusted accordingly if renal insufficiency occurs, e. g. even temporarily with exsiccosis.

Assessment

Geriatric assessment refers to functional tests that are available as a diagnostic tool for recording resources and deficits and quantifying them in geriatric patients. Implementation and evaluation, etc. see www.kcgeriatrie.de

Secondary diseases

For diabetic secondary diseases, also in advanced age, the statements by the NVL [5] on diabetes and retinopathy, nephropathy, diabetic foot syndrome and neuropathy apply in principle. Some particularities in elderly people are highlighted below as examples:

Diabetic foot [8]

• Diagnostics: in contrast to monofilament examination, the examination of vibration sensation with the 128-Hertz tuning fork can be omitted in patients of advanced age.

• Therapy: the multi-professional geriatric team is an indispensable addition in the treatment of elderly and geriatric patients with diabetic foot syndrome.

• Prophylaxis: when selecting footwear, the risk of falling should be taken into account, e. g. in patients at risk of falling, metatarsal bars should not be used.

Coronary heart disease (CHD)

• Revascularization of coronary vessels in elderly diabetic patients remains a challenge due to the lack of randomized studies comparing percutaneous coronary intervention (PCI) with bypass surgery, especially in elderly people with diabetes.

• Meta-analyses suggest that PCI is beneficial in elderly people with diabetes with single-vessel disease, while bypass surgery is the better choice in triple-vessel disease.

• In clinically-relevant cardiovascular disease, after exhaustion of non-drug basic therapy, primary oral hypoglycemic agents should be used to control type 2 diabetes, which reduce the risk of the occurrence of a cardiovascular event. The NVL recommends a combination of metformin and SGLT-2 inhibitors/or GLP-1 receptor agonist.

Acute coronary syndrome

• Diabetes with acute coronary syndrome is associated with a lower rate of successful coronary revascularization and the risk of periinterventional complications in elderly people compared to younger people.

• Insulin therapy should be started in patients with hyperglycemia>10 mmol/l in the acute phase of acute coronary syndrome, taking into account the comorbidities.

Stroke

• In the context of an acute stroke, older diabetes patients with blood glucose levels>198 mg/dl (>11 mmol/l) should be consistently treated with insulin, as there is evidence that hyperglycemia increases stroke volume and is associated with a poorer functional outcome.

• In a large randomized study, intensified insulin therapy with only slightly to moderately-elevated serum glucose levels (mean 137 mg/dl (7.6 mmol/l)) had no effect on mortality and functional outcome in patients and cannot be recommended in general, especially due to the risk of hypoglycemic episodes [9].

Therapy

Non-drug treatments are also the basis of treatment for elderly people with diabetes. In addition to the recommendations of the NVL, there are particularities:

Training

Elderly people with diabetes should also participate in structured diabetes training. A special evaluated training program (SGS) is currently available for the group of functionally-impaired patients and is also available in many foreign languages [10]. If possible, relatives and friends should also participate in such a program.

Movement and tendency to fall

• Elderly people with diabetes mellitus should be checked for a possible risk of falling.

• In elderly people with diabetes and an increased risk of falling, medication should be reviewed with regard to drugs that increase the tendency to fall (e. g. neuroleptics, hypnotics, sedatives).

• Elderly people with diabetes should have their visual acuity regularly checked and, if necessary and possible, they should be offered the option of correcting it.

• Functionally mildly or severely-impaired elderly people with diabetes and their relatives should be made aware of possibilities for fall prevention and of fall hazards at home (lack of lighting, missing handles in the bathroom and near the toilet, etc.)

• Functionally mildly or severely-impaired elderly people, especially those with frailty and diabetes, should be offered opportunities for strength and endurance training.

• Exercise is considered the most important lifestyle measure for the prevention of dementia in advanced age.

Nutrition

• The consequences of malnutrition are serious in advanced age. Elderly people who are overweight or obese should avoid strict dietary restrictions due to the risk of malnutrition.

• The risk of malnutrition can be assessed using a Mini Nutritional Assessment (MNA).

• In underweight patients, the causes should be clarified by a multi-professional team.

Oral antidiabetics and GLP-1 agonists

Advantages mentioned for the individual substances apply to monotherapy. In combination with insulin or insulinotropic substances (e. g. sulfonylureas, glinides), the increased risk of side effects (e. g. risk of hypoglycemia) should be taken into account. Combinations of>2 oral antidiabetics (OADs) should be avoided in view of the risks of polypharmacotherapy in advanced age.

Acarbose, glitazones, sulfonylureas and glinides are considered by the majority to be less suitable. For use in advanced age, the FORTA recommendations (Fit for The Aged) [11] can also be consulted.

Metformin

Metformin is also to be used as a drug therapy of first choice for elderly patients, although clinical studies on the administration of metformin in advanced age are not available (FORTA Recommendation B). In clinically-relevant renal and/or cardiovascular disease, NVL primarily recommends combination therapy of metformin plus SGLT-2 inhibitors/or GLP-1 agonists.

If metformin is used, patients should be carefully advised to discontinue/pause metformin in situations where there is a risk of acute deterioration in kidney function (examination with X-ray contrast agents, surgery under general anesthesia, febrile diseases, exsiccosis or gastrointestinal infections). Metformin can be prescribed up to a glomerular filtration rate of>30 ml/min in a maximum dose of 1000 mg, divided into two single doses. Vitamin B 12 deficiency may occur after prolonged metformin intake.

DPP-4 inhibitors

DPP-4 inhibitors can be used in elderly patients, according to FORTA first choice (Recommendation A) for elderly patients [11]. Advantages can be seen in particular with regard to therapy adherence (low frequency of administration required), risk of hypoglycemia, weight neutrality and higher degree of renal failure (dose reduction).

GLP-1 agonists

GLP1 agonists can be used in elderly patients in individual cases (SIRD) (FORTA Recommendation B). Advantages can include: low risk of hypoglycemia, weight loss – if this is also the aim of therapy [12]; for liraglutide, dulaglutide and semaglutide [13, 14]: reduced cardiovascular morbidity and mortality; for dulaglutide and semaglutide [16]: administration once a week. Dulaglutide and semaglutide are available in higher dosages. Pre-filled syringes of dulaglutide are easy-to-use. Semaglutide is also available as in pill form.

NVL T2DM recommends the use of GLP-1 agonists in cases of clinically-relevant cardiovascular comorbidity. GLP-1 agonists should be selected that reduce the desired cardiovascular endpoint (see NVL [5]).

SGLT-2 inhibitors (gliflozin)

SGLT-2 inhibitors can be used in elderly patients. In clinically-relevant cardiovascular disease, an SGLT-2 inhibitor should be used in combination with metformin as a first-line therapy if non-drug measures are not sufficient to achieve the individual therapeutic goal.

The start of therapy with dapagliflozin is not recommended after the age of 75 years; for empagliflozin a limit of 85 years applies. Advantages can include: lowering of blood glucose levels without personal risk of hypoglycemia and reduced cardiovascular morbidity and mortality, avoidance of hospitalization due to heart failure as well as a nephroprotective effect in patients with type 2 diabetes [17, 18]. During use, increased risks, e. g. for urogenital infections, polyuria, exsiccosis and deterioration of renal function as well as the (rare) occurrence of (normoglycemic) ketoacidosis and Fournier gangrene should be noted. SGLT-2 inhibitors have an antihypertensive effect. SGLT-2 inhibitors lead to weight loss, which is undesirable in frailty.

For metformin and SGLT-2 inhibitors, the recommendation to pause the medication in times of increased stress (as with taking “sick days”) has proven to be effective.

Sotagliflozin and dapagliflozin are also approved for insulin therapy in obese people (BMI>=27 kg/m²) with type 1 diabetes.

Insulin

• Insulin therapy should be started if lifestyle changes and/or oral antidiabetics do not achieve the individualized therapy goal or oral antidiabetics are no longer effective due to contraindications or if polypharmacy can be reduced.

• Before insulin therapy, it should be decided whether insulin should be given as monotherapy or in combination with oral antidiabetics. The choice of insulin therapy depends primarily on the patient’s wishes, cognitive and fine motor skills as well as the social environment and the therapeutic goal.

• The money counting test [19] is suitable for assessing whether independent insulin therapy can be successful.

The following particularities apply especially to geriatric patients: Short-acting insulins (normal and analog insulins):

• For safety reasons, all short-acting insulins can be given after the start of a meal without an injection-to-meal interval or in the case of loss of appetite or dementia.

  Long-acting insulins (neutral protamine Hagedorn [NPH] and analog insulins):

• The rate of nocturnal hypoglycemia is lower among analog basal insulins with a normoglycemic therapy target than among NPH insulins [21]. Cloudy NPH insulins have the disadvantage that they must be mixed well before injection.

• Provided that the patient consumes regular meals and exercises, mixed insulins can be used if fewer injections and blood glucose tests are desired.

• Insulin degludec can be injected at variable injection times, which makes it easier to administer e. g. by nursing services.

The care of patients in domestic and long-term inpatient care

Complex insulin therapy regimens are often used at an advanced age with a too strict setting. At the same time, there is insufficient communication between general practitioners and nurses regarding insulin therapy, and emergency instructions are rarely available.

Technology

Technical aids for diabetes management for the elderly have been on the market for many years. While mechanical aids such as ageappropriate blood glucose meters or age-appropriate insulin pens are already well-established and well-accepted, electronic aids (e. g. pillboxes with reminder function) or digital aids (PC programs or apps) have not yet found widespread use.

The evaluation of individual aids can be found in Practice Tool 4 (see Appendix).

Blood glucose self-monitoring

Blood glucose self-monitoring should be carried out individually and within the scope of the possibilities (self-care competence) of the patient and the relatives caring for him/her.

In the case of strongly fluctuating blood glucose levels and in a transition phase, the use of flash glucose monitoring (FGM)/continous glucose monitoring (CGM) is also helpful in older people with diabetes and improves the quality of life.

Geriatric syndromes and special situations in advanced age

Frailty and sarcopenia

Frailty and sarcopenia are two geriatric syndromes which are of great importance for the preservation of functionality, independence, and quality of life of the elderly.

Frailty is a multidimensional syndrome characterized by decreased functional reserves, reduced resistance to stresses and increased vulnerability to negative health events such as falls, institutionalization and mortality [22]. Frailty is diagnosed on the basis of five criteria (Practice Tool) that describe a physical phenotype.

Sarcopenia is the age-associated loss of muscle mass and muscle function, often associated with weakness and the risk of falling. Both occur more frequently in elderly people with diabetes than in the population without diabetes.

• Sarcopenia/frailty screening should be performed in elderly patients with diabetes.

• An optimized diet and adapted training programs should be the basis of therapy for sarcopenia and frailty.

• In patients with an increased rate of falls and fractures, measures should be taken to prevent falls.

Depression

Depression is a common mental disorder among elderly people with diabetes. A bidirectional relationship is known and also a mutual negative influence on physical activity, compliance/adherence, or dementia [23]. With some limitations, elderly patients with diabetes can be treated in the same way as younger patients.

• Elderly people with diabetes should be screened for depression once a year. If the result is positive, a validated, age-specific procedure should be performed.

• Elderly people with diabetes and depression should pay particular attention to signs of possible suicidal tendencies due to the increased risk of suicide.

• Interventions that promote physical activity and social contacts should be used in treating depression.

Dementia

In Germany there are currently about 1.7 million people with dementia. People with type 2 diabetes have a higher risk of dementia in advanced age compared to people without diabetes [24]. Dementia has a negative impact on other geriatric syndromes, especially frailty, and is associated with poorer metabolic control and an increased risk of hypoglycemia.

• In elderly people with diabetes, a screening of cognitive performance should be performed once a year using a validated method.

• The cognitive requirements of diabetes treatment should be adapted to the cognitive performance of the person with diabetes.

• Training measures should be adapted to the cognitive abilities of people with diabetes and the complexity of the content and level of language taught should be adapted accordingly.

• Activating the body and encouraging physical activity should be encouraged within the existing physical abilities of an elderly person with diabetes and dementia.

Urinary incontinence

• Diabetic cystopathy is often associated with diabetic neuropathy [25]. Polyneuropathy should therefore always be a reason for the examination of bladder function.

• Elderly people with diabetes should have an incontinence assessment at least once a year.

• Indwelling catheters should be avoided if possible; an indication for an indwelling catheter for urinary incontinence is only given if all other options fail, are rejected or cannot be applied.

Special features in care

• The planning and evaluation of care should always be evidence-based and should incorporate current expert standards German Network for Quality Development in Nursing (DNQP) and interdisciplinary care guidelines Association of the Scientific Medical Societies in Germany (AWMF).

• The situation and risk assessment should always be carried out together with the family doctor and all professional groups involved in the care.

• Screening/assessment tools should be shared in the exchange of information across the different areas of care (primary care, hospital, outpatient, and long-term inpatient care, etc.).

• The care focus of geriatric patients with diabetes should include the following: avoidance of hypoglycemia, prevention of diabetic foot syndrome, recording of pain (especially with regard to polyneuropathies), monitoring of the skin, wound assessment, wound management, and promotion of oral health, recording of the nutritional situation, preservation and promotion of continence and recording of mobility restrictions/danger of falling.

• Changes in the care needs of vulnerable geriatric patients with diabetes should be communicated immediately and in a standardized way to the subsequent care levels/providers (managing the transition of care) in order to seamlessly integrate the adaptation of medical, nursing and therapeutic services.

• Nursing documentation should always be used in joint case planning across occupational groups.

• When taking oral antidiabetics, the timing should be chosen to match the prescribed drug/group of drugs.

• When insulin or insulinotropic drugs (especially sulfonylureas) are administered, sufficient food intake should be ensured to avoid hypoglycemia. When using insulinotropic drugs in nursing homes/outpatient care, it is advisable to leave instructions for the caregivers in the event of an acute complication such as severe hypoglycemia. In case of severe hypoglycemia (with loss of consciousness), nasal glucagon can be easily administered by first responders.

• In order to ensure subcutaneous insulin injection, the cannula length should be selected to suit the patient’s constitution.

• Pen needles should not be used more than once.

• To avoid lipohypertrophy, the (varying) injection site should be determined in a rotation plan.

• The injection site should be chosen with regard to the speed of insulin absorption, any skin lesions or lipohypertrophies and recorded in a rotation plan.

• Elderly people with diabetes who carry out their insulin therapy and metabolic control themselves should be regularly assessed for their cognitive and sensorimotor abilities, especially when they are adjusting or changing their therapy. Certain tests from geriatric assessment are suitable for this purpose.

• Training content should be coordinated across the different levels of care, but above all between the hospital, family doctor and home care, and thus jointly safeguarded.

The proportion of diabetes patients among the elderly of at least 25–30% is very high across all care facilities, outpatient services, homes, and clinics. At the same time, access to diabetological expertise for this patient group is low and not guaranteed for all regions. In order to ensure that diabetes patients in need of care are provided with guideline-based care no matter their location, a separate training pillar “Diabetes Care” has been added to the training program of the German Diabetes Society (DDG). The continuing education pillar consists of a basic qualification as well as continuing education to become a DDG diabetes care specialist with additional designation of the field of activity “long-term” or “clinical” (see www.deutsche-diabetes-gesellschaft.de).

Since the majority of people in need of care with diabetes are cared for at home by relatives, it is also important to make these relatives a special diabetes training offer. Currently, only one Dia Life training program of the Verband der Diabetes-Beratungs- und Schulungsberufe in Deutschland (VDBD) (see www.vdbd.de) is being evaluated. Diabetes content is also included in small parts in the Allgemeine Ortskrankenkasse (AOK)-funded family care (www.aok.de/gp/pflegekurse). However, the Working Group Geriatrics and Care of the DDG is currently examining the possibilities of expanding and focusing these programs on the needs of geriatric patients with diabetes.

Attachment: Practice Tools

Practice Tool 1 Test procedure of geriatric assessment and its importance for the domains of diabetes treatment

Area	Particularities	Test procedure	Short and practical
Training	Cognition testing, special curriculum/media required, training of relatives and caregivers/nursing care staff	Visual acuity, hearing, clock-completion test, Mini Mental State Examination (MMSE) (acc. to Folstein), timed test of money counting, DemTect, Geriatric Depression Scale (GDS)	Clock-completion test, timed test of money counting
Movement	Exercise therapy made difficult, realistic recommendations (walking) useful, effects on bones, fall/fractures, cognition	Timed Up & Go, five-chair-rise, Short Physical Performance Battery (SPPB), Tinetti Test	Timed Up & Go
Nutrition	Frequent malnutrition in advanced age, usual nutritional recommendations (whole grain, losing weight) not reasonable, realistic recommendations necessary for everyday life	Condition of dentures, endoscopic evaluation of swallowing, Mini-Nutritional Assessment (MNA), Nutritional Risk Screening 2002 (NRS-2002)	MNA screening
Pharmacotherapy	Consider polypharmacy and susceptibility to iatrogenic damage, compliance is determined by cognition and depression, use insulin when necessary	Check of the ability to take medication, timed test of money counting

Practice Tool 2 General therapy goals in terms of improving the quality of life

• Avoidance of acute complications (especially hypoglycemia)

• Minimization of the side effects of the therapy (e. g. severe hypoglycemia) and of stress on the patient caused by the therapy (avoidance of polypharmacy)

• Reduction of geriatric syndromes

• Increasing the competence (empowerment) of those affected in dealing with the disease

• Reduction of a disease stigma

• Treatment satisfaction

• Promotion of therapeutic adherence through individually-adapted therapy

• Regular monitoring of the understanding of therapy (cognitive, sensorimotor, psychological) and the individual options

• Prevention and treatment of symptoms by improving the metabolic control

• Treatment and improvement of comorbidities

• Avoidance of overtreatment by reducing polypharmacy where possible

• Checking medication lists for missing medication if, for example, cardiovascular or renal events with subsequent impairment of quality of life can thus be prevented

• Avoidance of overdiagnosis, where possible

Practice Tool 3 HbA1c target corridor

The NVL T2DM provides a corridor for the HbA1c target areas, which is based on the following parameters: Life expectancy, comorbidity, polypharmacotherapy, risk of hypoglycemia and drug interactions, burden of therapy, resources and possibilities of support, functional and cognitive abilities, duration of diabetes, patient’s wishes ([Fig. 2]). It is very noteworthy that for the first time, aspects and problem areas of the elderly with diabetes are explicitly included in a national care guideline, in particular, the criteria “polymedication” and “functional and cognitive abilities”, which often affect the geriatric patient ([Fig. 2]).

Fig. 2 HbA1c target corridor. Source: German Medical Association (Bundesärztekammer – BÄK), Associations of Statutory Health Insurance Physicians (Kassenärztliche Bundesvereinigung – KBV), Working Group of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – AWMF). National Care Guideline (Nationale Versorgungsleitlinie) Type 2 Diabetes – Partial publication of the long version, 2nd edition. Version 1. 2021 [rerif].

Practical Tool 4 Technology for the Elderly

Mechanical aids:

• Magnifying glasses and other visual aids, speaking BG measuring device (very suitable)

• BG meters which do not require calibration, with a large display and easy operation (very suitable)

• Insulin pens with easy release and low thumb pressure (very suitable)

• Step-by-step instructions integrated into everyday objects (very suitable)

• Pillboxes with weekly supply (very suitable)

  Technical aids for elderly people with diabetes in a broader sense:

• Automatic blood pressure monitors, preferably with upper arm cuff and electric pump

• Walking aids for polyneuropathy and/or frailty (e. g. walking frame, walker)

• Fracture prevention (e. g. safe hip protection pants, anti-slip socks)

  Electronic aids:

• PC programs for analyzing collected measured values and data (partly suitable)

• Apps to improve therapy compliance (partially suitable)

• Apps for data management and BG control (partly suitable)

• Technical aids to remind patients to take medication or inject insulin (partially suitable)

• Automatic lighting with motion sensors to prevent falls (very suitable)

• Sensor mats or Radio Frequency Identification (RFID)/Global-Positioning-System (GPS) systems to improve safety, for example in the case of dementia (limited suitability)

• Flash glucose monitoring (FGM) sensors are easy to use even for elderly people with diabetes and can lead to improved blood glucose control and better quality of life.

• Continuous glucose monitoring (CGM) systems are only suitable for some elderly people due to more complex operation

• FGM and CGM systems, especially when integrated into electronic patient records, can make an important contribution to continuous and better metabolic control of people in need of care with diabetes and insulin therapy in outpatient and inpatient care. This would make it possible to carry out therapy corrections in good time and avoid unnecessary hospital admissions.

German Diabetes Association: Clinical Practice Guidelines
This is a translation of the DDG clinical practice guideline published in Diabetologie 2022; 17 (Suppl 2): S226–S236 DOI 10.1055/a-1886-3846

Conflicts of Interest

AB has received lecture fees from Bayer, Böhringer Ingelheim, Pfizer, Daiichi Sankyo, Lilly, Novo Nordisk, Novartis and Sanofi-Aventis. AZ has received lecture fees from Berlin-Chemie, Boehringer Ingelheim, Lilly, Novo Nordisk and Sanofi-Aventis. JW has received honoraria for speaking from Pfizer, Novo Nordisk, Sanofi-Aventis, Novartis, Chiesi and Boehringer Ingelheim.

• References

• 1 Bahrmann A, Bahrmann P, Baumann J. et al. AWMF S2k-Leitlinie Diabetes im Alter, S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Diabetologie 2018; 13: 423-489
• 2 Wernecke J, Bahrmann A, Zeyfang A. Individuelle Therapieziele bei betagten Diabetespatienten. Diabetologe 2012; 8: 108-112
• 3 Hodeck K, Tittel SR, Dreyhaupt I. et al. Charakteristika von Diabetespatienten mit und ohne Pflegebedürftigkeit. Diabetologie 2020; 15: 392-399
• 4 Budnitz DS, Lovegrove MC, Shehab N. et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012
• 5 German Medical Association (Bundesärztekammer – BÄK), Associations of Statutory Health Insurance Physicians (Kassenärztliche Bundesvereinigung – KBV), Working Group of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – AWMF). Nationale Versorgungsleitlinie Typ-2-Diabetes – Teilpublikation der Langfassung. 2021; 2. Auflage. Version 1
• 6 Lacy ME, Gilsanz P, Eng Ch. et al. Severe Hypoglycemia and Cognitive Function in Older Adults With Type 1 Diabetes: The Study of Longevity in Diabetes (SOLID). Diabetes Care 2019; 43: 541-548
• 7 Beckett NS, Peters R, Fletcher AE. et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898
• 8 Bahrmann A, Wernecke J. Der geriatrische Patient mit diabetischem Fußsyndrom. Diabetologe 2022; 18: 225-231
• 9 Kansagara D, Fu R, Freeman M. et al. Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med 2011; 154: 268-282
• 10 Zeyfang A, Feucht I, Fetzer G. et al. Eine strukturierte geriatrische Diabetiker-Schulung (SGS) ist sinnvoll. Diabetes 2001; 10: 203-207
• 11 Wehling M, Burkhardt H. Hrsg. Arzneimitteltherapie für Ältere. 5. Aufl.. Heidelberg: Springer; 2019
• 12 Pfeffer MA, Claggett B, Diaz R. et al. for the ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247-2257
• 13 Marso SP, Daniels GH, Brown-Frandsen K. et al. for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322
• 14 Marso SP, Bain SC, Consoli A. et al. for the SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844
• 15 Holman RR, Bethel A, Mentz RJ. et al. for the EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 1228-1239
• 16 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide an cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019; 394: 121-130
• 17 Zinman B, Wanner Ch, Lachin JM. et al. for the EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
• 18 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
• 19 Zeyfang A, Berndt S, Aurnhammer G. et al. A short easy test can detect ability for autonomous insulin injection by the elderly with diabetes mellitus. J Am Med Dir Assoc 2012; 13: 81.e15-81.e8.1E18
• 20 McMurray JJV, Solomon SD, Inzucchi SE. et al. for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008
• 21 Rosenstock J, Dailey G, Massi-Benedetti M. et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955
• 22 Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 2007; 62: 722-727
• 23 Kulzer B, Albus C, Herpertz S et al. Psychosoziales und Diabetes – Teil 1. S2-Leitlinie Psychosoziales und Diabetes – Langfassung. Diabetologie 2013; 8: 198-242 und Teil 2. Diabetologie 2013: 8: 292–324
• 24 Cheng G, Huang C, Deng H. et al. Diabetes as a risk factor for dementia and mild cognitive im-pairment: a meta-analysis of longitudinal studies. Intern Med J 2012; 42: 484-491
• 25 Jackson SL, Scholes D, Boyko EJ. et al. Urinary incontinence and Diabetes in Postmeopausal Women. Diabetes Care 2005; 28: 1730-1738

Publication History

Article published online:
13 January 2023